TISSUE-BASED SMALL ANIMAL MODEL FOR HIV DRUG DISCOVERY

用于艾滋病毒药物发现的基于组织的小动物模型

• 批准号: 6348654
• 负责人: Cheryl Stoddart
• 金额: $ 97.07万
• 依托单位: J. DAVID GLADSTONE INSTITUTES
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-08-01 至 2007-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6348654
• 关键词: SCID mouse; antiAIDS agent; biological models; drug discovery /isolation; drug screening /evaluation; model design /development

The National Institute of Allergy and Infectious Diseases (NIAID) supports a comprehensive portfolio of contract resources to discover and develop novel therapeutic agents for the prevention and treatment of infections caused by Human Immunodeficiency Virus-1 (HIV-1), AIDS-associated opportunistic pathogens, and other infectious agents. Animal model resources constitute one element of this drug discovery and development program. The purpose of the present project is to provide a resource for evaluating potential therapeutics for HIV-1 infection. Details regarding access by the scientific community are provided at: http://www.niaid.nih.gov/daids/pdatguide/overview.htm The contractor is responsible for i) evaluating therapeutic agents, alone and in combination, for efficacy and toxicity in vitro and in the SCID-hu thymus/liver animal model; ii) performing quality assurance/control of the components of the in vitro and in vivo assay systems, to insure reproducible evaluation of candidate therapies; iii) determining optimal routes and schedules of administration; iv) modifying the model system as necessary, to augment its usefulness for evaluating potential HIV-1 therapeutics; and 5) preparing and submitting periodic and interim reports.

美国国家过敏和传染病研究所 (NIAID) 支持全面的合同资源组合，以发现和开发新型治疗药物，用于预防和治疗人类免疫缺陷病毒-1 (HIV-1)、艾滋病相关机会性病原体引起的感染和其他传染源。 动物模型资源构成了该药物发现​​和开发计划的要素之一。 本项目的目的是为评估 HIV-1 感染的潜在疗法提供资源。 有关科学界访问的详细信息，请访问： http://www.niaid.nih.gov/daids/pdatguide/overview.htm 承包商负责 i) 评估单独和联合治疗药物的体外和 SCID-hu 胸腺/肝脏动物模型中的功效和毒性； ii) 对体外和体内测定系统的组件进行质量保证/控制，以确保候选疗法的可重复评估； iii) 确定最佳给药途径和时间表； iv) 根据需要修改模型系统，以增强其评估潜在 HIV-1 疗法的有用性； 5) 准备并提交定期报告和中期报告。

项目成果

Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice.

HIV-1 成熟抑制剂 bevirimat 在 SCID-hu Thy/Liv 小鼠中的有效活性。

• 发表时间: 2007-11-28
• 影响因子: 3.7
• 作者: Stoddart, Cheryl A;Joshi, Pheroze;Sloan, Barbara;Bare, Jennifer C;Smith, Philip C;Allaway, Graham P;Wild, Carl T;Martin, David E
• 通讯作者: Martin, David E

Effects of IL-7 on early human thymocyte progenitor cells in vitro and in SCID-hu Thy/Liv mice.

IL-7 对体外和 SCID-hu Thy/Liv 小鼠早期人胸腺祖细胞的影响。

• 发表时间: 2003-07-15
• 作者: Napolitano, Laura A;Stoddart, Cheryl A;Hanley, Mary Beth;Wieder, Eric;McCune, Joseph M
• 通讯作者: McCune, Joseph M

Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals.

使用四类许可的抗逆转录病毒药物验证 SCID-hu Thy/Liv 小鼠模型。

• 发表时间: 2007-08-01
• 影响因子: 3.7
• 作者: Stoddart, Cheryl A;Bales, Cheryl A;Bare, Jennifer C;Chkhenkeli, George;Galkina, Sofiya A;Kinkade, April N;Moreno, Mary E;Rivera, José M;Ronquillo, Rollie E;Sloan, Barbara;Black, Paul L
• 通讯作者: Black, Paul L

Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice.

白蛋白缀合的 C34 肽 HIV-1 融合抑制剂：体外与 C34 和 T-20 等效，在 SCID-hu Thy/Liv 小鼠中具有持续活性。

• 发表时间: 2008-12-05
• 作者: Stoddart, Cheryl A;Nault, Geneviève;Galkina, Sofiya A;Thibaudeau, Karen;Bakis, Peter;Bousquet;Robitaille, Martin;Bellomo, Maryanne;Paradis, Véronique;Liscourt, Patricia;Lobach, Alexandra;Rivard, Marie;Ptak, Roger G;Mankow
• 通讯作者: Mankow

Human immunodeficiency virus type 1 Nef-mediated downregulation of CD4 correlates with Nef enhancement of viral pathogenesis.

人类免疫缺陷病毒 1 型 Nef 介导的 CD4 下调与 Nef 增强病毒发病机制相关。

• 发表时间: 2003-02
• 作者: Stoddart, Cheryl A;Geleziunas, Romas;Ferrell, Sharon;Linquist;Moreno, Mary E;Bare, Christopher;Xu, Weiduan;Yonemoto, Wes;Bresnahan, Patricia A;McCune, Joseph M;Greene, Warner C
• 通讯作者: Greene, Warner C